Tetra Bio-Pharma Announces Awarding of NSERC Engage Grant Partnership to Grow Pros MMP and McGill University $TBP.ca

Tbp_large

Announce that the National Sciences and Engineering Research Council of Canada (NSERC) has awarded ~y NSERC Engage Grant partnership to MMP and Dr. Stan Kubow of McGill University

As concern of MMP’s mission to spot and offer new products to consumers, with the award of the NSERC Engage union grant, MMP will establish a first research collaboration with McGill University and plans to endue in this program both financially and by in-kind contributions

OTTAWA, ONTARIO–(Oct. 19, 2016) – Grow Pros MMP Inc. (MMP), a assistant of Tetra Bio-Pharma Inc. (“TetraBio” or the “Company” or “TBP“) (CSE:TBP) is pleased to blazon that the National Sciences and Engineering Research Council of Canada (NSERC) has awarded an NSERC Engage Grant partnership to MMP and Dr. Stan Kubow of McGill University.

As dividend of MMP’s mission to give variety to and offer new products to consumers, with the award of the NSERC Engage society grant, MMP will establish a primeval research collaboration with McGill University and plans to invest in this program both financially and through in-kind contributions to pursue its investigation and development objectives and become a cosmos leader in the development and commercialization of Cannabis-based products.

“The company with McGill University is in stripe with MMP’s vision to stretch commercial operations and prepare to throw Cannabis sativa-derived supplement/retail or deaden with narcotics products for the North American market. This project will allow the development of intellectual property to protect that will be products that would be commercialized through TBP,” commented Ryan Brown.

“The proposed collaboration betwixt Dr S. Kubow, Associate Professor, McGill University, relates to MMP’s want to develop an extraction process and to open products using specific fractions of the scatter seed Cannabis sativa. Fractions with the highest dermal and parole absorption will subsequently be characterized to more distant understand the pharmacology of these extracts,” commented Dr. Randy Ringuette, Ph.D. Medical Researcher, MMP Inc.

Dr. Stan Kubow fixed, “We are excited by the collaboration by MMP that will allow us to turn to account systematic state-of-the-art investigation methodologies to identify bioactives from Cannabis sativa according to the development of science-based consumer products.”

According to Mr. A. Rancourt CEO of TBP, “We are to a high degree pleased by the decision of NSERC to bestow this partnership grant. This has implications with regard to both MMP and AgroTek.” He added, “This is in ancestry with TBP’s vision to tend MMP a leader in the progress to maturity of Cannabis sativa derived products concerning the consumer market and for the commercialization of genuine supplements derived from Cannabis sativa by AgroTek.”

About Dr. Stan Kubow

Dr. S. Kubow, Ph.D. is ~y Associate Professor at the School of Dietetics and Human Nutrition, McGill University. His inquiry interests include the impact of nutritional interventions in successi~ a variety of disease outcomes and metabolic disorders using technologically modified fare extracts and isolates with enhanced bioactivity including phytochemical extracts, whey and soy proteins and probiotics. These studies have been focused upon oxidative stress, inflammatory indices, lipoprotein, fatty acid and glucose metabolism as related to cell signaling pathways and illness pathogenesis.

The Canadian Securities Exchange (CSE) has not reviewed this intelligence release and does not accept duty for its adequacy or accuracy.

Forward-looking statements

Some statements in this absolution may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates power of determination or may occur in the to come (including, without limitation, statements regarding possible acquisitions and financings) are forward-looking statements. Forward-looking statements are in the main identifiable by use of the discourse “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these war of ~ or other variations on these altercation or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of what one. are beyond the Company’s faculty to control or predict, that may efficient ~ the actual results of the Company to think ~ently materially from those discussed in the front-looking statements. Factors that could attempt actual results or events to be unlike materially from current expectations include, mixed other things, without limitation, the disability of the Company, through its totally-owned subsidiary, GrowPros MMP Inc., to gain a licence for the production of sanatory marijuana; failure to obtain sufficient financing to effect the Company’s business plan; rivalry; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s notorious disclosure record on file with the suitable securities regulatory authorities. Although the Company has attempted to become identical important factors that could cause actual results or events to differ materially from those described in early-looking statements, there may be other factors that bring into existence results or events not to be as anticipated, estimated or intended. Readers should not paragraph undue reliance on forward-looking statements. The progressive-looking statements included in this word release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such front-looking statements to reflect new knowledge, subsequent events or otherwise unless required ~ the agency of applicable securities legislation.

Tetra Bio-Pharma Inc.
Ryan Brown
VP Business Development and Communications

Tetra Bio-Pharma Inc.
Andre Rancourt
Chief Executive Officer
(613) 421-8402
Investors@tetrabiopharma.com

Tags: #smallcapstocks, $TSXV

I am unfailing that along with having difficulties by anxiety, my mother suffered from blues – never really addressed clinically or in some other way.

Recent Comments

    Archives